Verastem's duvelisib delight not so sweet for AbbVie and Novartis
Cancer drug developer Verastem (Nasdaq: VSTM) might have found a jewel on the scrapheap, if newly-presented Phase III results are anything to go by.
In a deal with fellow US company Infinity Pharmaceuticals (Nasdaq: INFI) last year, Verastem licensed exclusive worldwide rights to develop and commercialize Infinity’s duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
It was agreed for Verastem to pay up to $28 million in milestones, with duvelisib at that point viewed as a troubled blood cancer drug. Earlier in 2016, Infinity had reported disappointing data in a mid-stage trial, leading to the company’s previous partner, US drugmaker AbbVie (NYSE: ABBV), to end an alliance that could have been worth up to $805 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze